E. Peter Greenberg, PhD, Program Director and Director, Microbiology Core –
http://depts.washington.edu/micro/faculty/greenberg.htm

Dr. Greenberg is a Professor of Microbiology and is a Multi-PI with Dr. Ramsey. In addition, Dr. Greenberg is also the Director for the Microbiology Core of the Seattle CFRTC. Dr. Greenberg is currently Director of the UW CF Foundation supported Research Development Program (RDP). He has served continuously as a member of the CFF Research and research Training Committee for the past 12 years. He is an elected member of the National Academy of Sciences and the American Academy of Arts and Sciences. He has made major contributions to our understanding of the fundamental biology underlying the chronicity of CF lung infections and the regulation of virulence gene expression in P. aeruginosa and other CF pathogens. Dr. Greenberg is an authority on microbemicrobe interactions. This is an area of increasing relevance as we come to understand that the CF lung represents a polymicrobial community. Furthermore, as research efforts on the intestinal microbiota of CF patients begins to move ahead this expertise will be invaluable. Dr. Greenberg is currently located on the third floor of the K-wing of UW Medicine in laboratories adjacent to the CF Foundation supported RDP Biofilm Core.

Greenberg Lab web page, see http://depts.washington.edu/epglab/index.html

Colin Manoil, PhD http://www.gs.washington.edu/faculty/manoil.htm is an expert on the genetics and genomics of CF pathogens. He has developed a variety of critical methods that have led to rapid progress in our understanding of P. aeruginosa biology and he has recently turned his attention to identification of new targets for CF therapeutic development by using his high-throughput methods. He will oversee our mutant repository and our phenotype screening service facility. Dr. Manoil is a member of the Genome Sciences Department at UW Medicine. His laboratory is housed in the Foege Building, which is next door to and approximately a one-minute walk from the K wing.

Jane Burns, MD http://www.seattlechildrens.org/medical-staff/Jane-L-Burns/ Dr. Burns' primary area of research for many years has been cystic fibrosis (CF) microbiology, including antibiotic resistance and bacterial pathogenesis. Her studies have used both in vitro and in vivo models of infection. Novel methods of in vitro susceptibility testing have been established, including testing drug activity against bacteria grown in biofilms and examining drug bioactivity in the presence of CF sputum. She has worked with both primary CF cells and immortalized cell lines in tissue culture to examine bacterial pathogenesis including attachment, invasion and apoptosis. In vivo experiments use a mouse model of chronic bacterial infections with Pseudomonas aeruginosa and Burkholderia cepacia complex. Recent work is examining the phenotypic and genotypic adaptations of both organisms to growth within the CF airway. Dr. Burns frequently collaborates with clinical and basic science CF researchers at Seattle Children's Hospital and the University of Washington. In addition, she directs the Center for CF Microbiology at Seattle Children's Hospital, which is a core laboratory for the CF Foundation Therapeutics Development Network.

Matthew Parsek, PhD http://depts.washington.edu/micro/faculty/parsek.htm is a fundamental microbiologist who has made major contributions to our understanding of biofilm biology with particular relevance to CF. Much of his current work is focused on the matrix that binds bacteria into a biofilm. He is the Director of our CFF-supported RDP Biofilm Core. He is responsible for day-to-day operations of the biofilm research resources for the CFRTC.